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Abstract
In recent years, the use of adaptive design methods in clinical research and development based on
accrued data has become very popular due to its flexibility and efficiency. Based on adaptations
applied, adaptive designs can be classified into three categories: prospective, concurrent (ad hoc),
and retrospective adaptive designs. An adaptive design allows modifications made to trial and/or
statistical procedures of ongoing clinical trials. However, it is a concern that the actual patient
population after the adaptations could deviate from the originally target patient population and
consequently the overall type I error (to erroneously claim efficacy for an infective drug) rate may
not be controlled. In addition, major adaptations of trial and/or statistical procedures of on-going
trials may result in a totally different trial that is unable to address the scientific/medical questions
the trial intends to answer. In this article, several commonly considered adaptive designs in clinical
trials are reviewed. Impacts of ad hoc adaptations (protocol amendments), challenges in by design
(prospective) adaptations, and obstacles of retrospective adaptations are described. Strategies for
the use of adaptive design in clinical development of rare diseases are discussed. Some examples
concerning the development of Velcade intended for multiple myeloma and non-Hodgkin's
lymphoma are given. Practical issues that are commonly encountered when implementing adaptive
design methods in clinical trials are also discussed.
1 Introduction
In the past several decades, it is recognized that increasing
spending of biomedical research does not reflect an
increase of the success rate of pharmaceutical (clinical)
development. Woodcock (2005) indicated that the low
success rate of pharmaceutical development could be due
to (i) a diminished margin for improvement that escalates
the level of difficulty in proving drug benefits, (ii) genom-
ics and other new science have not yet reached their full
potential, (iii) mergers and other business arrangements
have decreased candidates, (iv) easy targets are the focus
as chronic diseases are harder to study, (v) failure rates
have not improved, (vi) rapidly escalating costs and com-
plexity decreases willingness/ability to bring many candi-
dates forward into the clinic [1]. As a result, the United
States Food and Drug Administration (FDA) kicked off a
Critical Path Initiative to assist the sponsors in identifying
the scientific challenges underlying the medical product
pipeline problems. In 2006, the FDA released a Critical
Path Opportunities List that calls for advancing innovative
trial designs, especially for the use of prior experience or
accumulated information in trial design. The Critical Path
Opportunities List interprets it as the encouragement for the
use of innovative adaptive design methods in clinical tri-
als and the potential use of Bayesian approach in clinical
research and development. The purpose of adaptive
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design methods in clinical trials is to give the investigator
the flexibility for identifying best (optimal) clinical bene-
fit of the test treatment under study without undermining
the validity and integrity of the intended study.
The concept of adaptive design can be traced back to
1970s when the adaptive randomization and a class of
designs for sequential clinical trials were introduced [2].
As a result, most adaptive design methods in clinical
research are referred to as adaptive randomization [3-6],
group sequential designs with the flexibility for stopping
a trial early due to safety, futility and/or efficacy [7-13],
and sample size re-estimation at interim for achieving the
desired statistical power [14-16]. The use of adaptive
design methods for modifying the trial and/or statistical
procedures of on-going clinical trials based on accrued
data has been practiced for years in clinical research.
Adaptive design methods in clinical research are very
attractive to clinical scientists due to the following rea-
sons. First, it reflects medical practice in real world. Sec-
ond, it is ethical with respect to both efficacy and safety
(toxicity) of the test treatment under investigation. Third,
it is not only flexible, but also efficient in the early and late
phase of clinical development. However, it is a concern
whether the p-value or confidence interval regarding the
treatment effect obtained after the modification is reliable
or correct. In addition, it is also a concern that the use of
adaptive design methods in a clinical trial may lead to a
totally different trial that is unable to address scientific/
medical questions that the trial is intended to answer
[17,18].
In recent years, the potential use of adaptive design meth-
ods in clinical trials have attracted much attention. The
Pharmaceutical Research and Manufacturers of America
(PhRMA) and Biotechnology Industry Organization
(BIO) have established adaptive design working groups
and proposed strategies, methodologies, and implemen-
tations for regulatory consideration [19]. However, there
are no universal agreement in terms of definition, meth-
odologies, and applications. Many journals have pub-
lished special sections and/or issues on adaptive design.
These journals included, but are not limited to, Biometrics
(Vol. 62, No. 3), Statistics in Medicine (Vol. 25, No. 19),
Journal of Biopharmaceutical Statistics (Vol. 15, No. 4
and Vol. 17, No. 6), Biometrical Journal (Vol. 48, No. 4),
and Pharmaceutical Statistics (Vol. 5, No. 2). For a com-
prehensive summarization of the issues and recommen-
dations for the use of adaptive design methods, readers
many consult with [18] and [20].
The purpose of this article is multi-fold. First, it is to pro-
vide a comprehensive review of adaptive design methods
in clinical research and development. Second, it is not
only to outline challenges in prospective adaptations,
impact on concurrent adaptations, and obstacles of retro-
spective adaptations being made of on-going trials, but
also to discuss issues that are commonly encountered
when implementing adaptive design methods in clinical
trials. Third, it is to discuss strategies for clinical develop-
ment of rare diseases using adaptive design methods. In
the next section, commonly employed adaptations and
the resultant adaptive designs are briefly described. Also
included in this section are regulatory and statistical per-
spectives regarding the use of adaptive design methods in
clinical trials. The impact of protocol amendments, chal-
lenges of by design adaptations, and obstacles of retro-
spective adaptations when applying adaptive design
methods in clinical trials are discussed in Section 3. In Sec-
tion 4, strategies for the use of adaptive design in clinical
development of rare diseases are discussed. Also included
in this section are some trial examples concerning the
development of Velcade (intended for multiple myeloma
and non-Hodgkin's lymphoma). Practical issues that are
commonly encountered when implementing adaptive
design methods in clinical trials are discussed in Section 5.
Some concluding remarks are given in the last section.
2 What is adaptive design?
In clinical trials, it is not uncommon to modify trial and/
or statistical procedures during the conduct of clinical tri-
als based on the review of interim data. The purpose is not
only to efficiently identify clinical benefits of the test treat-
ment under investigation, but also to increase the proba-
bility of success of clinical development. Trial procedures
are referred to as the eligibility criteria, study dose, treat-
ment duration, study endpoints, laboratory testing proce-
dures, diagnostic procedures, criteria for evaluability, and
assessment of clinical responses. Statistical procedures
include randomization, study design, study objectives/
hypotheses, sample size, data monitoring and interim
analysis, statistical analysis plan, and/or methods for data
analysis. In this article, we will refer to the adaptations (or
modifications) made to the trial and/or statistical proce-
dures as the adaptive design methods. Thus, an adaptive
design is defined as a design that allows adaptations to
trial and/or statistical procedures of the trial after its initi-
ation without undermining the validity and integrity of
the trial [21]. In their recent publication, with the empha-
sis of the feature of by design adaptations only (rather
than ad hoc adaptations), the PhRMA Working Group on
Adaptive Design refers to an adaptive design as a clinical
trial design that uses accumulating data to decide on how
to modify aspects of the study as it continues, without
undermining the validity and integrity of the trial [19]. In
many cases, an adaptive design is also known as a flexible
design.Orphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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2.1 Adaptations
An adaptation is referred to a modification or a change
made to trial and/or statistical procedure during the con-
duct of a clinical trial. By definition, adaptations that are
commonly employed in clinical trials can be classified
into the categories of prospective adaptation, concurrent
(or ad hoc) adaptation, and retrospective adaptation. Pro-
spective adaptations include, but are not limited to, adap-
tive randomization, stopping a trial early due to safety,
futility or efficacy at interim analysis, dropping the losers
(or inferior treatment groups), sample size re-estimation,
and etc. Thus, prospective adaptations are usually referred
to as by design adaptations as described in the PhRMA
white paper [19]. Concurrent adaptations are usually
referred to as any ad hoc modifications or changes made
as the trial continues. Concurrent adaptations include,
but are not limited to, modifications in inclusion/exclu-
sion criteria, evaluability criteria, dose/regimen and treat-
ment duration, changes in hypotheses and/or study
endpoints, and etc. Note that concurrent adaptations are
generally not envisioned as candidates for change initially
but their needs become apparent as the trial continues.
Retrospective adaptations are usually referred to as modi-
fications and/or changes made to statistical analysis plan
prior to database lock or unblinding of treatment codes.
In practice, prospective, ad hoc, and retrospective adapta-
tions are implemented by study protocol, protocol
amendments, and regulatory reviewer's consensus, respec-
tively.
2.2 Type of adaptive designs
Based on (primarily prospective) adaptations employed,
commonly considered adaptive design methods in clini-
cal trials include, but are not limited to: (i) an adaptive
randomization design, (ii) a group sequential design, (iii)
a sample size re-estimation design, (iv) a drop-the-loser
design, (v) an adaptive dose finding (e.g., dose escalation)
design, (vi) a biomarker-adaptive design, (vii) an adaptive
treatment-switching design, (viii) a hypothesis-adaptive
design, (ix) an adaptive seamless phase II/III trial design,
and (x) a multiple adaptive design. These adaptive design
methods are briefly described below.
Adaptive randomization design
An adaptive randomization design is a design that allows
modification of randomization schedules based on varied
and/or unequal probabilities of treatment assignment in
order to increase the probability of success (Figure 1) [See
Additional file 1]. Commonly applied adaptive randomi-
zation procedures include treatment-adaptive randomiza-
tion [3,4], covariate-adaptive randomization, and
response-adaptive randomization [5,6]. Although an
adaptive randomization design could increase the proba-
bility of success (so-called play-the-winner), it may not be
feasible for a large trial or a trial with a relatively long
treatment duration because the randomization of a given
subject depends on the response of the previous subject. A
large trial or a trial with a relatively long treatment dura-
tion utilizing adaptive randomization design will take a
much longer time to complete. Besides, randomization
schedule may not be available prior to the conduct of the
study. Moreover, statistical inference on treatment effect is
often difficult to obtain if it is not impossible due to com-
plicated probability structure as the result of adaptive ran-
domization.
Group sequential design
A group sequential design is a design that allows for pre-
maturely stopping a trial due to safety, futility/efficacy or
both with options of additional adaptations based on
results of interim analysis. Various stopping boundaries
based on different boundary functions for controlling an
overall type I error rate are available in the literature (see,
e.g., Lan and DeMets, 1987; Wang and Tsiatis, 1987;
Rosenberger et al., 2001; Jennison and Turnbull, 2000,
2005; Chow and Chang, 2006). In recent years, the con-
cept of two-stage adaptive design has led to the develop-
ment of the adaptive group sequential design (e.g., Cui,
Hung, and Wang, 1999; Posch and Bauer, 1999; Leh-
macher and Wassmer, 1999; Liu, Proschan, and Pledger,
2002). It should be noted that the standard methods for
group sequential design may not be appropriate (i.e., it
may not be able to control the overall type I error rate at
the desired level of 5%) if there is a shift in target patient
population due to additional adaptations or protocol
amendments.
Sample size re-estimation design
A sample size re-estimation design is referred to as an
adaptive design that allows for sample size adjustment or
re-estimation based on the observed data at interim (Fig-
ure 2). Sample size adjustment or re-estimation could be
done in either a blinding or unblinding fashion based on
the criteria of treatment effect-size, conditional power,
and/or reproducibility probability (see, e.g., [9,14-16],
and [22-26]). Sample size re-estimation suffers from the
Response-adaptive randomization Figure 1
Response-adaptive randomization.Orphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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same disadvantage as the original power analysis for sam-
ple size calculation prior to the conduct of the study
because it is performed by treating estimates of the study
parameters, which are obtained based on data observed at
interim, as true values. It is not a good clinical/statistical
practice to start with a small number and then perform
sample size re-estimation (adjustment) at interim by
ignoring the clinically meaningful difference that one
wished to detect for the intended clinical trial. It should be
noted that the observed difference at interim based on a
small number of subjects may not be of statistically signif-
icance (i.e., it may be observed by chance alone). Thus,
standard methods for sample size re-estimation based on
the observed difference with a limited number of subjects
may be biased and misleading.
Drop-the-losers design
A drop-the-losers design is a design that allows dropping
the inferior treatment groups. A drop-the-losers design
also allows adding additional arms. A drop-the-losers
design is useful in phase II clinical development especially
when there are uncertainties regarding the dose levels [27-
30]. The selection criteria and decision rules play impor-
tant roles for drop-the-loser designs. Dose groups that are
dropped may contain valuable information regarding
dose response of the treatment under study. Typically,
drop-the-loser design is a two-stage design. At the end of
the first stage, the inferior arms will be dropped based on
some pre-specified criteria. The winners will then proceed
to the next stage. In practice, the study is often powered
for achieving a desired power at the end of the second
stage (or at the end of the study). In other words, there
may not be any statistical power for the analysis at the end
of the first stage for dropping the losers (or picking up the
winners). In this case, it is a common practice to drop the
losers or pick up the winners based on so-called precision
analysis, i.e., an approach for determining the confidence
level for achieving a statistical significance. Note that
some clinical scientists prefer the term pick-the-winner
designs.
Adaptive dose finding design
An adaptive dose finding (e.g., escalation) design is often
used in early phase clinical development to identify the
minimum effective dose (MED) and/or the maximum tol-
erable dose (MTD), which is used to determine the dose
level for the next phase clinical trials [31-33]. For adaptive
dose finding design, the method of continual re-assess-
ment method (CRM) in conjunction with Bayesian
approach is usually considered [34-36]. Mugno et al.
(2004) introduced a nonparametric adaptive urn design
approach for estimating a dose-response curve [37]. More
details regarding PhRMA's current position and proposed
statistical methods, the reader should consult with a spe-
cial issue recently published at the Journal of Biopharmaceu-
tical Statistics, Vol. 17, No. 6.
Biomarker-adaptive design
A biomarker-adaptive design is a design that allows for
adaptations based on the response of biomarkers such as
genomic markers. An-adaptive biomarker design involves
biomarker qualification and standard, optimal screening
design, and model selection and validation. It should be
noted that there is a gap between identifying biomarkers
that associated with clinical outcomes and establising a
predictive model between relevant biomarkers and clini-
cal outcomes in clinical development. For example, corre-
lation between biomarker and true clinical endpoint
makes a prognostic marker. However, correlation between
biomarker and true clinical endpoint does not make a pre-
dictive biomarker.
A prognostic biomarker informs the clinical outcomes, inde-
pendent of treatment. They provide information about
the natural course of the disease in individuals who have
or have not received the treatment under study. Prognos-
tic markers can be used to separate good- and poor-prog-
nosis patients at the time of diagnosis. A predictive
biomarker informs the treatment effect on the clinical end-
point ([20]).
A biomarker-adaptive design can be used to (i) select right
patient population (e.g., enrichment process for selection
of a better target patient population), (ii) identify nature
course of disease, (iii) early detection of disease, and (iv)
help in developing personalized medicine (see, e.g., [20]
and [38,39]).
Adaptive treatment-switching design
An adaptive treatment-switching design is a design that
allows the investigator to switch a patient's treatment
from an initial assignment to an alternative treatment if
Sample size re-estimation Figure 2
Sample size re-estimation.Orphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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there is evidence of lack of efficacy or safety of the initial
treatment (see, e.g., [36] and [40]). In oncology clinical
trials, estimation of survival is a challenge when treat-
ment-switching has occurred in some patients. A high per-
centage of subjects who switched due to disease
progression could lead to change in hypotheses to be
tested. In this case, sample size adjustment for achieving a
desired power is necessary.
Adaptive-hypotheses design
An adaptive-hypotheses design refers to a design that
allows modifications or changes in hypotheses based on
interim analysis results [41]. Adaptive-hypotheses designs
often considered before database lock and/or prior to data
unblinding. Some examples include the switch from a
superiority hypothesis to a non-inferiority hypothesis and
the switch between the primary study endpoint and the
secondary endpoints. For the switch from a superiority
hypothesis to a non-inferiority hypothesis, the selection
of non-inferiority margin is critical which has an impact
on sample size adjustment for achieving the desired
power. According to the ICH guideline, the selected non-
inferiority margin should be both clinical and statistical
justifiable.
Adaptive seamless phase II/III design
An adaptive seamless phase II/III trial design is referred to
a program that addresses within single trial objectives that
are normally achieved through separate trials in phase IIb
and phase III of clinical development. An adaptive seam-
less phase II/III design (Figure 3) is an adaptive seamless
phase II/III trial design that would use data from patients
enrolled before and after the adaptation in the final anal-
ysis [42,43]. An adaptive seamless phase II/III design is a
two-stage design consisting of a so-called learning stage
(phase IIb) and a confirmatory stage (phase III). A typical
approach is to power the study for the phase III confirma-
tory phase and obtain valuable information with certain
assurance using confidence interval approach at the phase
II learning stage. Its validity and efficiency, however, has
been challenged [44]. Moreover, it is not clear how to per-
form a combined analysis if the study objectives (or end-
points) are similar but different at different phases [45].
More research is needed.
Multiple adaptive design
Finally, a multiple-adaptive design is any combinations of
the above adaptive designs. Commonly considered multi-
ple-adaptation designs include (i) the combination of
adaptive group sequential design, drop-the-losers design,
and adaptive seamless trial design and (ii) adaptive dose-
escalation design with adaptive randomization [18]. In
practice, since statistical inference for a multiple-adapta-
tion design is often difficult, it is suggested that a clinical
trial simulation be conducted to evaluate the performance
of the resultant multiple adaptive design at the planning
stage.
Phase II/III seamless trial design Figure 3
Phase II/III seamless trial design.Orphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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2.3 Statistical and regulatory perspectives
From regulatory point of view, the use of adaptive design
methods based on accrued data in clinical trials may
introduce operational bias such as selection bias, or bias
that results from the method of evaluation, early with-
drawal, and modification of treatment. Consequently, it
may not be able to preserve the overall type I error rate at
the pre-specified level of significance. In addition, the
naive p-values may not be correct and the corresponding
confidence intervals for the treatment effect may not be
reliable. Moreover, it may result in a totally different trial
that is unable to address the medical questions that origi-
nal study intended to answer. In practice, commonly seen
adaptations include, but are not limited to, (i) sample size
adjustment at interim, (ii) sample size allocation to treat-
ments, (iii) delete, add, or change treatment arms, (iv)
shift in target patient population such as changes in inclu-
sion/exclusion criteria, (v) change in statistical test strat-
egy, (vi) change in study endpoints, and (vii) change in
study objectives such as the switch from a superiority trial
to a non-inferiority trial. One of the drawbacks of adaptive
designs is that interpretation of trial results is difficult,
such as the clinically meaningful effect size for the treat-
ments under study [46].
From statistical point of view, major (or significant) adap-
tations to trial and/or statistical procedures could (i)
introduce bias/variation to data collection, (ii) result in a
shift in location and scale of the target patient population,
and (iii) lead to inconsistency between hypotheses to be
tested and the corresponding statistical tests. These con-
cerns will not only have an impact on the accuracy and
reliability of statistical inference drawn on the treatment
effect, but also present challenges to biostatisti-cians for
development of appropriate statistical methodology for
an unbiased and fair assessment of the treatment effect.
Note that although the flexibility of modifying study
parameters is very attractive to clinical scientists, several
regulatory questions/concerns arise. First, what level of
modifications to the trial procedures and/or statistical
procedures would be acceptable to the regulatory author-
ities? Second, what are the regulatory requirements and
standards for review and approval process of clinical data
obtained from adaptive clinical trials with different levels
of modifications to trial procedures and/or statistical pro-
cedures of on-going clinical trials? Third, has the clinical
trial become a totally different clinical trial after the mod-
ifications to the trial procedures and/or statistical proce-
dures for addressing the study objectives of the originally
planned clinical trial? These concerns should be addressed
by the regulatory authorities before the adaptive design
methods can be widely accepted in clinical research and
development.
3 Impact, challenges, and obstacles
3.1 Impact of protocol amendments
In practice, for a given clinical trial, it is not uncommon to
have 3–5 protocol amendments after the initiation of the
clinical trial. One of the major impacts of many protocol
amendments is that the target patient population may
have been shifted during the process, which may have
resulted in a totally different target patient population at
the end of the trial. A typical example is the case when sig-
nificant modifications are applied to inclusion/exclusion
criteria of the study protocol. As a result, the resultant
actual patient population following certain modifications
to the trial procedures is a moving target patient popula-
tion rather than a fixed target patient population. As indi-
cated in [18], the impact of protocol amendments on
statistical inference due to shift in target patient popula-
tion (moving target patient population) can be studied
through a model that link the moving population means
with some covariates [47]. Chow and Shao (2005)
derived statistical inference for the original target patient
population for simple cases [46].
3.2 Challenges in by design adaptations
In clinical trials, commonly employed prospective (by
design) adaptations include stopping the trial early due to
safety, futility, and/or efficacy, sample size re-estimation
(adaptive group sequential design), dropping the losers
(adaptive dose finding design), and combining two sepa-
rate trials into a single trial (adaptive seamless design).
These designs are typical multiple-stage designs with dif-
ferent adaptations. In this section, major challenges in
analysis and design are described. Recommendations and
future development for resolution are provided whenever
possible.
The major difference between a classic multiple-stage
design and an adaptive multiple-stage design is that an
adaptive design allows adaptations after the review of
interim analysis results. These by design adaptations
include sample size adjustment (re-assessment or re-esti-
mation), stopping the trials due to safety, efficacy/futility,
or dropping the losers (picking the winners). Note that
commonly considered adaptive group sequential design,
adaptive dose finding design, and adaptive seamless trial
design are special cases of multiple-stage designs with dif-
ferent adaptations. In this section, we will discuss major
challenges in design (e.g., sample size calculation) and
analysis (controlling type I error rate under moving target
patient population) of an adaptive multiple-stage design
with K – 1 interim analyses.
A multiple-stage adaptive group sequential design is very
attractive to sponsors in clinical development. However,
major (or significant) adaptations such as modification of
doses and/or change in study endpoints may introduceOrphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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bias/variation to data collection as the trial continues. To
account for these (expected and/or unexpected) biases/
variation, statistical tests are necessary adjusted to main-
tain the overall type I error and the related sample size cal-
culation formulas have to be modified for achieving the
desired power. In addition, the impact on statistical infer-
ence is not negligible if the target patient population has
been shifted due to major or significant adaptations and/
or protocol amendments. This has presented challenges to
biostatisticians in clinical research when applying a mul-
tiple-stage adaptive design. In practice, thus, it is worthy
pursuing the following specific directions that (i) deriving
valid statistical test procedures for adaptive group sequen-
tial designs assuming model, which relates the data from
different interim analyses, (ii) deriving valid statistical test
procedures for adaptive group sequential designs assum-
ing the random-deviation model, (iii) deriving valid Baye-
sian methods for adaptive group sequential designs, and
(iv) deriving sample size calculation formulas for various
situations. Tsiatis and Mehta (2003) showed that there
exists an optimal (i.e., uniformly more powerful) design
for any class of sequential design with a specified error
spending function. It should be noted that adaptive
designs do not require in general a fixed error spending
function [44]. One of major challenges for an adaptive
group sequential design is that the overall type I error rate
may be inflated when there is a shift in target patient pop-
ulation [48].
For adaptive dose finding design, Chang and Chow's
method can be improved by the following specific direc-
tions that (i) studying the relative merits and disadvantage
of their method under various adaptive methods, (ii)
examining the performance of an alternative method by
forming the utility first with different weights to the
response levels and then modeling the utility, and (iii)
deriving sample size calculation formulas for various situ-
ations. An adaptive seamless phase II/III design is a two-
stage design that consists of two phases namely a learning
(or exploratory) phase and a confirmatory phase. One of
the major challenges for designs of this kind is that differ-
ent study endpoints are often considered at different
stages for achieving different study objectives. In this case,
the standard statistical methodology for assessment of
treatment effect and for sample size calculation cannot be
applied.
For a two-stage adaptive design, the above described
method by Chang (2007b) can be applied [49]. Chang's
method, however like other stage-wise combination
methods, is valid under the assumption of constancy of
the target patient populations, study objectives, and study
endpoints at different stages.
3.3 Obstacles of retrospective adaptations
In practice, retrospective adaptations such as adaptive-
hypotheses may encounter prior to database lock (or
unblinding) and implemented through the development
of statistical analysis plan. To illustrate the impact of ret-
rospective adaptations, we consider the situation where
switching hypotheses between a superiority hypothesis
and a non-inferiority hypothesis. For a promising test
drug, the sponsor would prefer an aggressive approach for
planning a superiority study. The study is usually powered
to compare the promising test drug with an active control
agent.
However, the collected data may not support superiority.
Instead of declaring the failure of the superiority trial, the
sponsor may switch from testing superiority to testing the
following non-inferiority hypotheses. The margin is care-
fully chosen to ensure that the treatment of the test drug
is larger than the placebo effect and, thus, declaring non-
inferiority to the active control agent means that the test
drug is superior to the placebo effect. The switch from a
superiority hypothesis to a non-inferiority hypothesis will
certainly increase the probability of success of the trial
because the study objective has been modified to estab-
lishing non-inferiority rather than showing superiority.
This type of switching hypotheses is recommended pro-
vided that the impact of the switch on statistical issues and
inference (e.g., appropriate statistical methods) on the
assessment of treatment effect is well justified.
4 Strategies for clinical development of rare 
diseases
4.1 Adaptive design strategies
Clinical development of a new drug product is a lengthy
and costly process, which includes phases I to III clinical
development (prior to regulatory review and approval)
and phase IV clinical development (post-approval). For
life-threatening diseases or diseases with unmet medical
need (rare diseases), this lengthy clinical development
process is not acceptable. Thus, the use of adaptive design
methods in clinical trials is called for. The purpose is to
shorten the development process (speed) without com-
promising the safety and efficacy of the drug product
under investigation (validity) by maximizing the power
for identify best clinical benefit of the drug product under
investigation with limited number of subjects (efficiacy).
As a result, many adaptive design methods are developed
for archiving the ultimate goals of validity, efficiency, and
speed in clinical development. In practice, it however
should be noted that many other important factors
beyond statistical components may have an impact on the
development process. These factors include, but are not
limited to, patient enrollment, treatment durations, and
time required for regulatory review/approval.Orphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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Commonly considered strategies for the use of adaptive
design methods in clinical development include, but are
not limited to, adaptive dose finding, adaptive seamless
phase I/II in early clinical development, and adaptive
seamless phase II/III in late phase clinical development.
These strategies help in not only shortening the develop-
ment time in a more efficient way but also increasing the
probability of success in clinical development. As an
example, let us consider the development of a new drug
product for a rare disease of multiple myeloma (MM)
with unmet medical need. A traditional approach is to
conduct a typical phase I study for identifying the maxi-
mum tolerated dose (MTD), which is often considered as
the optimal dose for the late phase of clinical develop-
ment. In practice, there are several options that we can run
this study with several doses or dose schedules. For exam-
ple, this trial can be run with parallel dose groups or
sequentially with the test drug as a single or add-on agent.
The traditional approach will not be able to provide the
entire spectrum of the dose response of the test drug. On
the other hand, if we consider an adaptive approach, it
allows us to use more options at the beginning and drop
some of the arms (options) if they are either too toxic or
ineffective (activity too low or requires very high dose that
makes the treatment very costly biologic product may be
very costly). In addition, since the treatment arms are
often correlated, the information such as dose limiting
toxicity (DLT) from different arms can be synchronized
using methods such as Bayesian model [36].
Similar approaches can be used for phase II trials, phase I/
II, or phase II/III adaptive seamless design. In this
approach, the interim endpoint may be a marker such as
response rate or time to disease progression. Some of the
inferior arms can be dropped at interim. If some of the
arms are promising, we can apply different randomization
scheme to assign more patients to the superior arms (play-
the-winner). In this case, not only the total cost will not
increase, but also we will increase the chance of success
because the increase of sample size for the superior treat-
ment arms are most promising. In addition, the schedules
for the trial are similar because the total number of
patients remains unchanged. This adaptive design strategy
can be applied to phase III trials, but with much less arms.
For phase IV studies, the adaptive design can also be
applied. However, the situation is different because the
drug has been approved during phase IV clinical develop-
ment. The focus of phase IV clinical development will be
the safety rather than efficacy.
In what follows, adaptive design strategies are illustrated
through some trial examples regarding the development
of the drug product intended for the rare disease of multi-
ple myeloma. Without loss of generality, data are modi-
fied from actual trials for the illustration purpose.
4.2 Some trial examples
Example 1: Dose-finding (escalation) design
In a phase I oncology trial, suppose that the primary
objective is to identify the maximum tolerated dose
(MTD) for a new test drug. Based on the animal studies, it
is estimated that the toxicity (dose limiting toxicity rate) is
1% for the starting dose 25 mg/m2 (1/10 of the lethal
dose). The dose limiting toxicity (DLT) rate at MTD is
defined as 0.25 and the MTD is estimated to be 150 mg/
m2. A typical approach is to consider so-called 3+3 tradi-
tional escalation rule (TER). On the other hand, an adap-
tive type approach is to apply the continual re-assessment
method (CRM) in conjunction with a Bayesian approach.
We can compare the 3+3 TER approach and the Bayesian
CRM adaptive method through simulations. A logistic
toxicity model is chosen for the simulations. The dose
interval sequence is chosen to be the customized dose
increment sequence (Increment factors = 2, 1.67, 1.33,
1.33, 1.33, 1.33, 1.33, 1.33, 1.33). The evaluations of the
escalation designs are based on the criteria of safety, accu-
racy, and efficiency. Simulation results for all three meth-
ods for three different MTD scenarios are summarized in
Table 1.
In this example, as it can be seen that if the true MTD is
150 mg/m2; the TER approach underestimates MTD (125
mg/m2), while the Baysian CRM adaptive method also
slightly underestimates the MTD (141 mg/m2). The aver-
age number of patients required is 19.4 and 15.5 for the
TER approach and the Bayesian CRM adaptive method,
respectively. From a safety perspective, the average
number of DLTs is 2.9 and 2.5 per trial for the TER
approach and the Bayesian CRM, respectively. As a result,
the Bayesian CRM adaptive method is preferable.
Table 1: Summary of simulation results for the designs
Method Assumed True MTD Mean Predicted MTD Mean Number of Patient Mean Number of DLTs
3+3 TER 100 86.7 14.9 2.8
CRM 100 99.2 13.4 2.8
3+3 TER 150 125 19.4 2.9
CRM 150 141 15.5 2.5
3+3 TER 200 169 22.4 2.8
CRM 200 186 16.8 2.2Orphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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Example 2: Three-stage adaptive design for NHL trial
A phase III two parallel group Non-Hodgkin's Lymphoma
trial was designed with three analyses. The primary end-
point is progression-free survival (PFS), the secondary
endpoints are (1) overall response rate (ORR) including
complete and partial response and (2) complete response
rate (CRR). The estimated median PFS is 7.8 months and
10 months for the control and test groups, respectively.
Assume a uniform enrollment with an accrual period of 9
months and a total study duration of 23 months. The esti-
mated ORR is 16% for the control group and 45% for the
test group. The classic design with a fixed sample-size of
375 subjects per group will allow for detecting a 3-month
difference in median PFS with 82% power at a one-sided
significance level of α = 0:025: The first interim analysis
(IA) will be conducted on the first 125 patients/group (or
total N1 = 250) based on ORR. The objective of the first IA
is to modify the randomization. Specifically, if the differ-
ence in ORR (test-control), ΔORR > 0, the enrollment will
continue. If ΔORR ≤ 0, then the enrollment will stop. If the
enrollment is terminated prematurely, there will be one
final analysis for efficacy based on PFS and possible effi-
cacy claimed on the secondary endpoints. If the enroll-
ment continues, there will be an second interim analysis
based on PFS. The second interim analysis will could lead
to either claim efficacy or futility, or continue to the next
stage with possible sample-size reestimation. The final
analysis of PFS. When the primary endpoint (PFS) is sig-
nificant, the analyses for the secondary endpoints will be
performed for the potential claim on the secondary end-
points. During the interim analyses, the patient enroll-
ment will not stop. This example is modified slightly from
an ongoing adaptive trial (Figure 4).
Example 3: Two-stage drop-loser adaptive design for optimal 
treatment in a phase IV trial
For phase IV study, the adaptive design can also work well.
For example, after a year since an oncology drug in the
market, physicians have used the drug with different com-
binations for treating patients with MM. However, there is
a strong desire to know which combination is the best for
the patient populations. Many physicians have their own
experiences, no one has convincing data. Therefore, the
sponsor is planned a trial to investigate the optimal com-
bination for the drug. In this scenario, we can use much
smaller sample size than phase III trials because the issue
is not focused on the type-I control as the drug is
approved. The issue is that given a minimum clinically
meaningful difference (e.g., two weeks in survival), what
is the probability of the trial will be able to identify the
optimal combination. Again this can be done through
simulations, the strategy is to start with about five combi-
nations, drop inferior arms and calculate the probability
of selecting the best arm under different combinations of
sample size at the interim and final stages. In this adaptive
design, we will drop 2 arms based on the observed
response rate, i.e., the two arms with lowest observed
response rates will be dropped at interim analysis and the
rest three arms will be carried forward to the second stage.
The characteristics of the design are presented in Table 2
for different sample sizes.
Given the response rate 0.4, 0.45, 0.45, 0.5, and 0.6 for
the five arms and 91% power, if a traditional design is
used, there will be 9 multiple comparisons (adjusted
alpha = 0.0055 using Bonferroni method). The required
sample size for the traditional design is 209 per group or
a total of 1045 subjects comparing a total of 500 subjects
for the adaptive trial (250 at the first stage and 150 at the
second stage). In the case when the null hypothesis is true
(the response rates are the same for all the arms), it
doesn't matter too much which arm is choose as the opti-
mal.
Table 2: Simulation results of phase IV drop-the-loser design
Interim sample size 
per group
Final sample size 
per group
Probability of identifying 
the optimal arm
25 50 80.3%
50 100 91.3%
Note: response rate for the five arms: 0.4, 0.45, 0.45, 0.5, and 0.6.
Non-Hodgkin's lymphoma trial Figure 4
Non-Hodgkin's lymphoma trial.Orphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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5 Implementation of adaptive design in clinical 
trials
As indicated earlier, the use of adaptive design methods in
clinical trials is very attractive due to its flexibility and effi-
ciency for identifying best clinical benefits of the treat-
ment under investigation. The flexibility, however, may
introduce possible operational biases and consequently
have an impact on the overall type I error rate. Thus, some
practical issues that are commonly encountered when
implementing adaptive design methods in clinical trials
are necessarily considered to ensure the validity and integ-
rity of the clinical trials. These practical issues are key to
the success of the clinical trials utilizing adaptive design
methods.
5.1 Study planning
Before the implementation of an adaptive design in clini-
cal trials, the following practical issues are necessarily con-
sidered. First, the following questions should be
addressed in order for determining whether an adaptive
design is feasible for the intended trial:
￿ Will the adaptive design require extraordinary efforts for
implementation?
￿ Are the level of difficulty and the associated cost justifi-
able for the gain from the adaptive design?
￿ Will the implementation of the adaptive design delay
patient recruitment and prolong the duration of the
study?
￿ Would delayed responses diminish the advantage of the
adaptive design?
￿ How often will the unblinded analyses be practical, and
to whom should the data be unblinded?
￿ How should the impact of a Data Monitoring Commit-
tee's (DMC's) decisions regarding the trial (e.g., recom-
mending early stopping or other adaptations due to safety
concerns) be considered at the design stage?
Second, the following questions should be addressed to
ensure the validity of the adaptive design for the intended
trial:
￿ Will the unblinding cause potential bias in treatment
assessment?
￿ Will the implementation of the adaptive design destroy
the randomness?
Third, the following questions regarding the degree of
flexibility (e.g., sensitivity or robustness) are necessarily
considered:
￿ Will protocol deviations or violations invalidate the
adaptive method?
￿ How might an unexpected DMC action affect the power
and validity of the design?
When designing a trial, we should also consider how to
prevent premature release of the interim results to the gen-
eral public using information masks because releasing
information it could affect the rest of the trial and endan-
ger the integrity of the trial. Regarding study design, and
we strongly suggest early communication with the regula-
tory agency and DMC regarding the study protocol and
the DMC charter. For broader discussions of planning dif-
ferent adaptive designs, please see the PhRMA full white
papers on adaptive design (see, e.g., [16,19,43,46], and
[50-52])
5.2 Communication with regulatory agency
As indicated earlier, the primary concern when imple-
menting adaptive design methods in clinical trials is its
validity and integrity from regulatory perspective. It is a
concern whether the application of adaptive design meth-
ods may have introduced some unexpected operational
bias, which may have an impact on accuracy and reliabil-
ity of the obtained statistical inference. It is also a concern
whether the application of adaptive design methods is
able to control the overall type I error rate at the pre-spec-
ified level of significance. As a result, regulatory agencies
such as the US FDA request strategies or plans for prevent-
ing possible operation biases and for controlling the over-
all type I error rate be developed. In addition, the sponsors
are encourage to begin a dialogue about adaptive designs
with medical reviewers and/or statistical reviewers from
the regulatory agencies as early as possible (preferably at
least a year) before the planning of a trial. In a adaptive
design conference, an statistician from US FDA office for
adaptive design addresses some of the expectations for
regulatory submissions utilizing adaptive design([53]).
These expectations regarding a clinical trial utilizing adap-
tive design methods are summarized below:
￿ It should be prospectively planned;
￿ It should have valid statistical approaches on modifica-
tion of design elements that have alpha control and can be
defined in terms of ICH E-9 standard;
￿ It should have valid point estimates and confidence
interval estimates;Orphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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￿ It should build on experience from external trials;
￿ It should takes a learn and confirm approach;
￿ It should have standard operating procedures (SOPs)
and infrastructure for adaptive process monitoring to
avoid bias;
￿ It should have SOPs on adaptive design decisions; and
￿ It should includes documentation of actual monitoring
process, extent of compliance, and potential effect on
study results.
In order to meet the above expectations, it is critical to
communicate with the agency. The advantage for commu-
nicating with the regulatory agency early is that the regu-
latory agency could be of assistance in sharing the data or
at least the disease information or models available
within the agency. Building off external data and experi-
ence is sometimes a crucial element of adaptive design. As
indicated in The Pink Sheet (December 18 issue, 2006, p.
24), drug development is a knowledge-creating business
and the access to external data and experience is extremely
helpful when implementing adaptive design methods in
clinical trials.
5.3 Trial monitoring
In practice, it is recognized that there are often deviations
from the study protocol when conducting a clinical trial.
It is ethical to monitor the trials to ensure that individual
subjects are not exposed, or have limited exposure, to
unsafe or ineffective treatment regimens. For this purpose,
an independent DMC is usually established. The DMC
plays a critical role in monitoring clinical trials. There are
common issues that affect a DMC's decision, such as
short-term versus long-term treatment effects, early termi-
nation philosophies, response to early beneficial trends,
response to early unfavorable trends, and response where
there are no apparent trends [52,53]. It is recommended
that a DMC be established to monitor the trial when an
adaptive design is employed in clinical trials, especially
when many adaptations are considered for allowing
greater flexibility.
Stopping rules
The stopping rule chosen in the design phase serves as a
(statistical) guideline to the DMC, which will make a deci-
sion regarding whether to continue or stop the trial early
due to safety, efficacy, or futility [51]. If all aspects of the
conduct of the clinical trial adhered exactly to the condi-
tions stipulated during the design phase, the stopping rule
obtained during the design phase could be used directly.
However, there are usually complicated factors that must
be dealt with during the conduct of the trial.
Deviation of analysis schedule
DMC meetings are typically based on the availability of its
members, which may be different from the schedules set
at the design phase. The enrollment may be different from
the assumption made at the design phase. Deviation in
the analysis schedule will affect the stopping boundaries;
therefore, the boundaries should be recalculated based on
the actual schedules.
Deviation of efficacy variable estimation
The true variability of the response variable is never
known, but the actual data collected at interim analysis
may show that the initial estimates in the design phase are
inaccurate. Deviation in the variability could affect the
stopping boundaries. In this case, we may want to know
the likelihood of success of the trial based on current data,
which is known as conditional and predictive power, and
repeated confidence intervals. Similarly, the estimation of
treatment difference in response could be different from
the initial estimation in the design phase. This could lead
to an adaptive design or sample-size re-estimation [12].
Safety factors
Efficacy is not the only factor that will affect a DMC's deci-
sion. Safety factors are critical for the DMC to make an
appropriate recommendation to stop or continue the trial.
The term "benefit-risk ratio" is a most commonly used
composite criterion to assist in decision-making. In this
respect, it is desirable to know the likelihood of success of
the trial based on current data, i.e., the conditional power
or predictive power. The DMC may also weight the short-
term and long-term treatment effects in its recommenda-
tions.
Note that the commonly used tools for monitoring a
group sequential design are stopping boundaries, condi-
tional and predictive powers, futility index, and repeated
confidence interval. These tools can be used in other adap-
tive designs. Bayesian monitoring tools are appreciated
for different adaptive designs.
6 Concluding remarks
As indicated earlier, although the use of adaptive design
methods in clinical trials is motivated by its flexibility and
efficiency, there are still some challenge in implementa-
tion. Recently, there are many discussions are around the
flexibility, efficiency, validity, integrity, and implementa-
tions of various types of adaptive designs. When imple-
menting an adaptive design in a clinical trial, In practice,
it is recommended that a couple of principles that (i)
adaptation should not alter the quality of trial conduct
and (ii) type I error should be preserved must be followed
when implementing the adaptive design methods in
phase III clinical trials. Following these principles, some
basic considerations such as dose/dose regimen, studyOrphanet Journal of Rare Diseases 2008, 3:11 http://www.ojrd.com/content/3/1/11
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endpoints, treatment duration, and logistics should be
carefully evaluated for feasibility [46]. To maintain the
validity and integrity of an adaptive design with compli-
cated adaptations, it is strongly suggested that an inde-
pendent data monitoring committee (IDMC) should be
established. In practice, IDMC has been widely used in
group sequential design with adaptations of stopping a
trial early and sample size re-estimation. The role and
responsibility of an IDMC for a clinical trial using adap-
tive design should clearly defined. IDMC usually convey
very limited information to investigators or sponsors
about treatment effects, procedural conventions, and sta-
tistical methods with recommendations in order to main-
tain the validity and integrity of the study.
When applying adaptive design methods in clinical trials,
it is suggested that the feasibility of certain adaptations
such as changes in study endpoints/hypotheses be care-
fully evaluated to prevent from any possible misuse and
abuse of the adaptive design methods. It should also be
noted that although clinical trial simulation does provide
"a" solution not "the" solution for a complicated multiple
adaptive design. In practice, "how to validate the assumed
predictive model for clinical trial simulation?" is a major
challenge to both investigators and biostatisticians.
For a fair and unbiased assessment of treatment effect, the
impact of protocol amendments, the major challenges of
by design adaptations, and the obstacles of retrospective
adaptations prior to database lock and/or unblinding
must be carefully evaluated. However, thus far, statistical
methodology for addressing these issues (difficulties) are
not fully understood and well established, especially
under the framework of moving target patient population
as the result of protocol amendments. In a recent FDA/
PhRMA Workshop on adaptive design held November
2006, the FDA has announced to slow the escalating
momentum behind adaptive clinical trial designs to allow
time to craft better working definitions of the new models
and build a better base before moving forward. As a result,
it is suggested that effort should be directed to current
issues such as the impact of protocol amendments, chal-
lenges in by design adaptations, and obstacles of retro-
spective adaptations as described in the previous sections.
In summary, from the clinical point of view, adaptive
design methods reflect real clinical practice in clinical
development. Adaptive design methods are very attractive
due to their flexibility and are very useful especially in
early clinical development. From the statistical point of
view, the use of adaptive methods in clinical trials makes
current good statistics practice even more complicated.
The validity of the use of adaptive design methods is not
well established and fully understood. Guidelines regard-
ing the use of adaptive design methods must be developed
so that appropriate statistical methods and statistical soft-
ware packages can be developed accordingly. Regulatory
guidelines can not only prevent possible misuse and/or
abuse of adaptive design methods in clinical trials, but
also maintain the validity and integrity of the trial.
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